$PPCB
Propanc Biopharma, Inc. Stock $ppcb

$ppcb Overview Financials Valuation SEC Filings Company Website

2014 Form 10-K Financial Statement

#000114420414060984 Filed on October 14, 2014

Income Statement

Concept	2014	2013 Q2	2013
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$750.0K	$180.0K	$1.350M
YoY Change	-44.44%	-92.91%	-88.34%
% of Gross Profit
Research & Development	$8.168K	$10.00K	$12.34K
YoY Change	-33.83%		23.44%
% of Gross Profit
Depreciation & Amortization	$538.00	$0.00	$4.062K
YoY Change	-86.76%		-99.96%
% of Gross Profit
Operating Expenses	$761.2K	$190.0K	$1.362M
YoY Change	-44.11%	-92.52%	-88.25%
Operating Profit	-$761.2K		-$1.362M
YoY Change	-44.11%
Interest Expense	$93.15K	-$30.00K	$5.465K
YoY Change	1604.43%	200.0%	-127.33%
% of Operating Profit
Other Income/Expense, Net	-$116.6K		-$141.2K
YoY Change	-17.41%
Pretax Income	-$877.8K	-$220.0K	-$1.503M
YoY Change	-41.6%	-91.41%	-87.05%
Income Tax	-$48.27K	$0.00	-$60.46K
% Of Pretax Income
Net Earnings	-$829.6K	-$220.0K	-$1.443M
YoY Change	-42.5%	-91.41%	-87.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.433B	-$397.5M	-$2.492B
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2014	2013 Q2	2013
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.00K	$0.00	$0.00
YoY Change
Cash & Equivalents		$0.00	$0.00
Short-Term Investments
Other Short-Term Assets	$30.00K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$110.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
LONG-TERM ASSETS
Property, Plant & Equipment		$538.00	$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$1.747K	$0.00
YoY Change		-82.53%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$110.0K	$0.00	$0.00
Total Long-Term Assets	$0.00	$1.747K	$0.00
Total Assets	$110.0K	$1.747K	$0.00
YoY Change		-96.51%	-100.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$350.0K	$272.6K	$270.0K
YoY Change	29.63%	43.47%	42.11%
Accrued Expenses	$490.0K	$300.0K	$300.0K
YoY Change	63.33%	66.67%	66.67%
Deferred Revenue
YoY Change
Short-Term Debt	$470.0K	$160.0K	$160.0K
YoY Change	193.75%	6.67%	6.67%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.520M	$790.0K	$790.0K
YoY Change	92.41%	36.21%	36.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.520M	$790.0K	$790.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.520M	$790.0K	$790.0K
YoY Change	92.41%	36.21%	36.21%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$70.63K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.410M	-$792.5K	-$790.0K
YoY Change
Total Liabilities & Shareholders Equity	$110.0K	$1.747K	$0.00
YoY Change		-96.51%	-100.0%

Cashflow Statement

Concept	2014	2013 Q2	2013
OPERATING ACTIVITIES
Net Income	-$829.6K	-$220.0K	-$1.443M
YoY Change	-42.5%	-91.41%	-87.38%
Depreciation, Depletion And Amortization	$538.00	$0.00	$4.062K
YoY Change	-86.76%		-99.96%
Cash From Operating Activities	$226.4K	-$30.00K	-$130.0K
YoY Change	-274.19%	-50.0%	-23.53%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	310.0K	30.00K	130.0K
YoY Change	138.46%	50.0%	-23.53%
NET CHANGE
Cash From Operating Activities	$226.4K	-30.00K	-130.0K
Cash From Investing Activities	$0.00	0.000	0.000
Cash From Financing Activities	310.0K	30.00K	130.0K
Net Change In Cash	$226.4K	0.000	0.000
YoY Change		-100.0%
FREE CASH FLOW
Cash From Operating Activities	$226.4K	-$30.00K	-$130.0K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	$226.4K	-$30.00K	-$130.0K
YoY Change	-274.19%	-50.0%	-23.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	0	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	72685	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	25000	USD
CY2013Q2	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	1209	USD
CY2014Q2	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	946	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	538	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16374781	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2013Q2	us-gaap	Assets Assets	1747	USD
CY2014Q2	us-gaap	Assets Assets	113745	USD
CY2013Q2	us-gaap	Bank Overdrafts BankOverdrafts	5	USD
CY2014Q2	us-gaap	Bank Overdrafts BankOverdrafts	0	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	272596	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	350004	USD
CY2013Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	16723353	USD
CY2014Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	422326	USD
CY2013Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	32879	USD
CY2014Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	17552917	USD
CY2014Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	33909	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-792476	USD
CY2013Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2014Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	272424	USD
CY2013Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2014Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	158244	USD
CY2013Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	57237	USD
CY2014Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	60350	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	70632	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1747	USD
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	251439	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	-1408314	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16104809	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-244589	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-302863	USD
CY2013	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-27549	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-141199	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1503099	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-60461	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-1442638	USD
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113745	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	1361900	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	761221	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-761221	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	121649	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	147369	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-226442	USD
CY2014	ppch	Prepaid Common Stock Issued For Services PrepaidCommonStockIssuedForServices	6667	USD
CY2014	ppch	Conversion Of Convertible Notes And Accrued Interest To Common Stock ConversionOfConvertibleNotesAndAccruedInterestToCommonStock	0	USD
CY2013	ppch	Discounts Related To Warrants Issued With Convertible Debenture DiscountsRelatedToWarrantsIssuedWithConvertibleDebenture	0	USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70632267	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72684767	shares
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12344	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8168	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-1361900	USD
CY2013	us-gaap	Interest Expense InterestExpense	5465	USD
CY2014	us-gaap	Interest Expense InterestExpense	93147	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	18	USD
CY2014	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-16522	USD
CY2013	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	-108185	USD
CY2014	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	0	USD
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-6959	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-116610	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-877831	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-48267	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-829564	USD
CY2013	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	114328	USD
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-58274	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1328310	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-887838	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72365530	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72350555	shares
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	803324	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	237833	USD
CY2013	ppch	Consultant Stock Expense ConsultantStockExpense	48000	USD
CY2014	ppch	Consultant Stock Expense ConsultantStockExpense	0	USD
CY2013	ppch	Amortization Of Prepaid Shares Issued For Services AmortizationOfPrepaidSharesIssuedForServices	38937	USD
CY2014	ppch	Amortization Of Prepaid Shares Issued For Services AmortizationOfPrepaidSharesIssuedForServices	6667	USD
CY2013	ppch	Write Off Of Subscription Receivable WriteOffOfSubscriptionReceivable	325	USD
CY2014	ppch	Write Off Of Subscription Receivable WriteOffOfSubscriptionReceivable	0	USD
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-27549	USD
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
CY2013	us-gaap	Depreciation Depreciation	4062	USD
CY2014	us-gaap	Depreciation Depreciation	538	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	49029	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-333	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	0	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1293	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-294	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	94607	USD
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	12965	USD
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	11598	USD
CY2014	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	158847	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-128647	USD
CY2013	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	5	USD
CY2014	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	-6	USD
CY2013	us-gaap	Payments For Loans PaymentsForLoans	32860	USD
CY2014	us-gaap	Payments For Loans PaymentsForLoans	45512	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	273959	USD
CY2013	us-gaap	Proceeds From Loans ProceedsFromLoans	37506	USD
CY2014	us-gaap	Proceeds From Loans ProceedsFromLoans	10542	USD
CY2013	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	123814	USD
CY2014	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	72158	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	128465	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	311141	USD
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3	USD
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3100	USD
CY2013	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-179	USD
CY2014	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	87799	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87799	USD
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	ppch	Conversion Of Accrued Interest To Common Stock ConversionOfAccruedInterestToCommonStock	1896	USD
CY2014	ppch	Conversion Of Accrued Interest To Common Stock ConversionOfAccruedInterestToCommonStock	0	USD
CY2013	ppch	Prepaid Common Stock Issued For Services PrepaidCommonStockIssuedForServices	0	USD
CY2013	ppch	Conversion Of Accrued Expenses To Common Stock ConversionOfAccruedExpensesToCommonStock	37500	USD
CY2014	ppch	Conversion Of Accrued Expenses To Common Stock ConversionOfAccruedExpensesToCommonStock	27500	USD
CY2013	ppch	Conversion Of Convertible Notes And Accrued Interest To Common Stock ConversionOfConvertibleNotesAndAccruedInterestToCommonStock	75000	USD
CY2013	ppch	Discounts Related To Lender Costs DiscountsRelatedToLenderCosts	0	USD
CY2014	ppch	Discounts Related To Lender Costs DiscountsRelatedToLenderCosts	30000	USD
CY2014	ppch	Discounts Related To Warrants Issued With Convertible Debenture DiscountsRelatedToWarrantsIssuedWithConvertibleDebenture	133095	USD
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Entity Registrant Name EntityRegistrantName	Propanc Health Group Corp
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001517681
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q4	dei	Entity Public Float EntityPublicFloat	5182094.20	USD
CY2014	dei	Trading Symbol TradingSymbol	PPCH
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82444100	shares
CY2014	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-27187	USD
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14513	USD
CY2014Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14968	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13975	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14968	USD
CY2014Q2	ppch	Loans From Related Party LoansFromRelatedParty	161975	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-492334	USD
CY2013	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	114328	USD
CY2014	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-58274	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-358917	USD
CY2014	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	226442	USD
CY2014Q2	ppch	Working Capital Deficit WorkingCapitalDeficit	1408314	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2012	ppch	Write Off Of Capitalized Patent Costs writeOffOfCapitalizedPatentCosts	27000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	17552917	USD
CY2013Q2	ppch	Loans From Related Party LoansFromRelatedParty	130689	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-274229	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	351935	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	92480	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	60461	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	48267	USD
CY2013Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	60461	USD
CY2014Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48267	USD
CY2013	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	443641	USD
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-127051	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.3275	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.3124	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.2341	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0.1054	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0402	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0550	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.0402	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.0550	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2420	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2968	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.2952	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	-0.1447	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0402	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0550	pure
CY2013Q2	us-gaap	Deferred Tax Assets Gross Current DeferredTaxAssetsGrossCurrent	18512	USD
CY2014Q2	us-gaap	Deferred Tax Assets Gross Current DeferredTaxAssetsGrossCurrent	50872	USD
CY2013Q2	us-gaap	Deferred Tax Liabilities Gross Current DeferredTaxLiabilitiesGrossCurrent	0	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Gross Current DeferredTaxLiabilitiesGrossCurrent	0	USD
CY2013	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	114328	USD
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-58274	USD
CY2013	ppch	Stock Issued During Period Value Conversion Of Accrued Expenses StockIssuedDuringPeriodValueConversionOfAccruedExpenses	146250	USD
CY2013	ppch	Write Off Of Subscription Receivables WriteOffOfSubscriptionReceivables	325	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	48000	USD
CY2013	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	0	USD
CY2013Q2	us-gaap	Deferred Tax Assets Gross Noncurrent DeferredTaxAssetsGrossNoncurrent	3996340	USD
CY2014Q2	us-gaap	Deferred Tax Assets Gross Noncurrent DeferredTaxAssetsGrossNoncurrent	4241995	USD
CY2013Q2	us-gaap	Deferred Tax Assets Valuation Allowance Noncurrent DeferredTaxAssetsValuationAllowanceNoncurrent	4014852	USD
CY2014Q2	us-gaap	Deferred Tax Assets Valuation Allowance Noncurrent DeferredTaxAssetsValuationAllowanceNoncurrent	4292867	USD
CY2013Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	-18512	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	-50872	USD
CY2013Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-60461	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-48267	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	13074	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	11016	USD
CY2009Q3	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	3.5% escalation clause or $1,052 per month
CY2013	ppch	Reimbursement On Goods And Service Tax Receivable Percentage ReimbursementOnGoodsAndServiceTaxReceivablePercentage	1	pure
CY2014	ppch	Reimbursement On Goods And Service Tax Receivable Percentage ReimbursementOnGoodsAndServiceTaxReceivablePercentage	1	pure
CY2014	us-gaap	Gain Loss On Foreign Currency Fair Value Hedge Derivatives GainLossOnForeignCurrencyFairValueHedgeDerivatives	2519	USD
CY2014	ppch	Fair Value Of Warrant Derivative Liability Recoreded As Debt Discount FairValueOfWarrantDerivativeLiabilityRecorededAsDebtDiscount	144241	USD
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3000000	shares
CY2014Q2	us-gaap	Share Price SharePrice	0.09
CY2013Q3	us-gaap	Share Price SharePrice	0.20
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	-537919	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	76896	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	244500	USD
CY2014	ppch	Stock Issued During Period Value Conversion Of Accrued Expenses StockIssuedDuringPeriodValueConversionOfAccruedExpenses	27500	USD
CY2013	ppch	Stock Issued During Period Value Issued For Services Two StockIssuedDuringPeriodValueIssuedForServicesTwo	663125	USD
CY2013	ppch	Stock Issued During Period Value Under Voluntary Ratchet StockIssuedDuringPeriodValueUnderVoluntaryRatchet	139158	USD
CY2013	ppch	Conversion Of Loan Payable To Convertible Debenture ConversionOfLoanPayableToConvertibleDebenture	0	USD
CY2014	ppch	Conversion Of Loan Payable To Convertible Debenture ConversionOfLoanPayableToConvertibleDebenture	27963	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from these estimates.  Significant estimates in the accompanying consolidated financial statements include the estimates of valuation of derivatives, <font style="BACKGROUND-COLOR: transparent">valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on translation dates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q3	ppch	Warrants Expire Period WarrantsExpirePeriod	P5Y
CY2013Q3	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	3000000	USD
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0698
CY2013	ppch	Prepaid Settlement Fee Paid Through Issuance Of Convertible Note PrepaidSettlementFeePaidThroughIssuanceOfConvertibleNote	0	USD
CY2014	ppch	Prepaid Settlement Fee Paid Through Issuance Of Convertible Note PrepaidSettlementFeePaidThroughIssuanceOfConvertibleNote	25000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-363703	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	260533	USD

Files In Submission

Name	View Source	Status
0001144204-14-060984-index-headers.html	Edgar Link	pending
0001144204-14-060984-index.html	Edgar Link	pending
0001144204-14-060984.txt	Edgar Link	pending
0001144204-14-060984-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_003.jpg	Edgar Link	pending
ppch-20140630.xml	Edgar Link	completed
ppch-20140630.xsd	Edgar Link	pending
ppch-20140630_cal.xml	Edgar Link	unprocessable
ppch-20140630_def.xml	Edgar Link	unprocessable
ppch-20140630_lab.xml	Edgar Link	unprocessable
ppch-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tex4-10pg01.jpg	Edgar Link	pending
tex4-10pg02.jpg	Edgar Link	pending
tex4-10pg03.jpg	Edgar Link	pending
tex4-10pg04.jpg	Edgar Link	pending
tex4-10pg05.jpg	Edgar Link	pending
tex4-10pg06.jpg	Edgar Link	pending
tex4-10pg07.jpg	Edgar Link	pending
tex4-10pg08.jpg	Edgar Link	pending
tex4-10pg09.jpg	Edgar Link	pending
tex4-11pg01.jpg	Edgar Link	pending
tex4-11pg02.jpg	Edgar Link	pending
tex4-11pg03.jpg	Edgar Link	pending
tex4-11pg04.jpg	Edgar Link	pending
tpg1.jpg	Edgar Link	pending
tpg10a.jpg	Edgar Link	pending
tpg10b.jpg	Edgar Link	pending
tpg13a.jpg	Edgar Link	pending
tpg13b.jpg	Edgar Link	pending
tpg16.jpg	Edgar Link	pending
tpg1a.jpg	Edgar Link	pending
tpg9.jpg	Edgar Link	pending
v390859_10k.htm	Edgar Link	pending
v390859_ex31-1.htm	Edgar Link	pending
v390859_ex32-1.htm	Edgar Link	pending
v390859_ex4-10.htm	Edgar Link	pending
v390859_ex4-11.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PPCB
Propanc Biopharma, Inc. Stock $ppcb

2014 Form 10-K Financial Statement

#000114420414060984 Filed on October 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB Propanc Biopharma, Inc. Stock $ppcb

2014 Form 10-K Financial Statement

#000114420414060984 Filed on October 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB
Propanc Biopharma, Inc. Stock $ppcb